At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 293 enrolled
Drug / intervention
CD07805/47 Gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
In Brief
A Phase 3 clinical trial evaluating CD07805/47 Gel and Placebo for Rosacea. Completed, enrolled 293 participants across 15 sites in 2 countries.
Detailed Summary
This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedMay 2011
Primary CompletionNov 2011
Study CompletionJan 2012
TodayJul 2026
First PostedMay 18, 2011
Enrollment StartMay 1, 2011
Primary CompletionNov 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.1 years ago
Interventions
CD07805/47 Geldrug
applied topically once daily
Placebodrug
applied topically once daily